Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering a compound of Formula (I), or a salt thereof, or a composition thereof to a subject (e.g., a human subject). Also provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108110 or a composition thereof to a subject (e.g., a human subject). In addition, provided herein are methods for treating a virus (e.g., an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108600 or a composition thereof to a subject (e.g., a human subject).

Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering a compound of Formula (I), or a salt thereof, or a composition thereof to a subject (e.g., a human subject). Also provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108110 or a composition thereof to a subject (e.g., a human subject). In addition, provided herein are methods for treating a virus (e.g., an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108600 or a composition thereof to a subject (e.g., a human subject).

The present invention is directed to compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2′, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

The present invention is directed to compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2′, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

The present invention is directed to compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2′, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

The present invention is directed to compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2′, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

The present invention is directed to compounds of Formula I:

##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

The present invention is directed to compounds of Formula I:

##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.